In the Media

Prof. Jonathan Gruber, MIT Innovation Fellow Brian Deese and Stanford doctoral student Ryan Cummings write for The New York Times about the health benefits of new weight-loss drugs and the risk they pose to American taxpayers. “The magnitude of potential benefit and potential cost — roughly $15,000 per year per person — posed by these drugs suggests that policymakers may have no alternative but to step in and bring their costs in line with their social benefits,” they write. “If policymakers succeed in doing so, we could build a model for drug price negotiation that enables an extraordinary medical breakthrough to improve both our health and our fiscal position.”